Adaptimmune Therapeutics Plc ADR (ADAP) concluded trading on Thursday at a closing price of $0.25, with 0.46 million shares of worth about $0.11 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -54.87% during that period and on July 03, 2025 the price saw a gain of about 3.14%. Currently the company’s common shares owned by public are about 257.85M shares, out of which, 228.63M shares are available for trading.
Stock saw a price change of 3.22% in past 5 days and over the past one month there was a price change of -13.43%. Year-to-date (YTD), ADAP shares are showing a performance of -76.19% which decreased to -53.59% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.20 but also hit the highest price of $1.48 during that period. The average intraday trading volume for Adaptimmune Therapeutics Plc ADR shares is 1.13 million. The stock is currently trading -2.12% below its 20-day simple moving average (SMA20), while that difference is down -7.53% for SMA50 and it goes to -52.75% lower than SMA200.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) currently have 257.85M outstanding shares and institutions hold larger chunk of about 34.07% of that.
The stock has a current market capitalization of $64.46M and its 3Y-monthly beta is at 2.23. It has posted earnings per share of -$0.27 in the same period. It has Quick Ratio of 1.79. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ADAP, volatility over the week remained 6.37% while standing at 7.38% over the month.
Stock’s fiscal year EPS is expected to drop by -75.44% while it is estimated to decrease by -50.43% in next year. EPS is likely to shrink at an annualized rate of -24.90% for next 5-years, compared to annual growth of 26.53% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Mizuho on June 26, 2025 offering a Neutral rating for the stock and assigned a target price of $0.50 to it. Coverage by H.C. Wainwright stated Adaptimmune Therapeutics Plc ADR (ADAP) stock as a Buy in their note to investors on July 30, 2024, suggesting a price target of $4 for the stock. On May 30, 2024, Scotiabank Initiated their recommendations, while on March 24, 2023, Bryan Garnier Initiated their ratings for the stock with a price target of $3.60. Stock get a Buy rating from Guggenheim on January 03, 2023.
